Adolor draws FDA rebuke for rep downplaying Entereg REMS
This article was originally published in Scrip
An Adolor representative's comments downplaying the reason behind the risk evaluation and mitigation strategy (REMS) for the bowel drug Entereg (alvimopan) have drawn a violation letter from the US FDA.
You may also be interested in...
Amivas requested a US tropical disease PRV for intravenous artesunate but FDA has not yet made a decision on eligibility; approval appears to block La Jolla’s competing product, currently under review, for seven years.
Providing information in a pre-IND meeting request will facilitate a more efficient development process, agency says in a new guidance; generally, there is insufficient information to assess if and when an emergency use authorization might be appropriate when a sponsor first enters discussions with the FDA.
CDER wants sponsors to use the NextGen Portal for electronic submission of promotional pieces to the Office of Prescription Drug Promotion, rather than sending in paper or physical media such as CDs; availability of this alternative pathway does not affect requirement for eCTD submission of some types of promotional materials starting in June 2021.